BioAgilytix secures new investment from Cinven
BioAgilytix, a global contract research organisation (CRO), is to be further capitalised by Cinven, which will acquire a majority stake in the business, while current majority investor Cobepa, a Brussels-based private investment firm, will remain a significant minority investor in the Company. Cobepa and GHO Capital, a specialist investor in